| Gene symbol | F | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | |
| Description | Fusion protein (F) | ||||
| GTO ID | GTC3671 |
| Trial ID | NCT06143046 |
| Disease | Respiratory Syncytial Virus Infectious Disease |
| Altered gene | F |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1345 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety and Immunogenicity in Infants Born to Vaccinated Mothers |
| Year | 2023 |
| Country | Canada|Chile|Denmark|Japan|Panama|South Africa|United Kingdom|United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1345-P201|2023-505359-37-00 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1345 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||